GlassScriptPhysician profile
Rose Karanicolas
NPI 1821393174
$1,522.73
in general payments reported to CMS, 2019-2025
11 companies · $840 in 2025
The $840 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.13 · 2022: $45.70 · 2023: $216 · 2024: $403 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $581.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $190.61 | 2024-2025 | Tezspire, Airsupra |
| Ars Pharmaceuticals Operations, INC. | $173.27 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $138.99 | 2023-2025 | Dupixent |
| Blueprint Medicines Corporation | $130.83 | 2025 | Ayvakit |
| Glaxosmithkline, LLC. | $120.81 | 2024 | Nucala |
| Kaleo, INC. | $69.55 | 2022-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $52.21 | 2025 | |
| Abbvie INC. | $25.82 | 2024 | |
| Optinose US, INC. | $20.96 | 2025 | |
| Sobi, INC | $18.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Karanicolas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.